Neurokinin B, Neurotensin, and Cannabinoid Receptor Antagonists and Parkinson Disease.

The neuropeptides neurokinin B, neurotensin, and anandamide, the endogenous ligands of NK₃, NT₁, and CB₁ receptors respectively, are known to interact with brain dopaminergic transmission. This study evaluated the effects of these three antagonists of the NK₃ (SR 142801), neurotensin (SR 48692), and cannabinoid (SR 141716) receptors on the severity of motor symptoms and levodopa-induced dyskinesias after administration of a single dose of levodopa in 24 patients with Parkinson disease. In this exploratory randomized, double-blind, placebo-controlled study, at the dose used, the drugs tested were well tolerated and could not improve parkinsonian motor disability. (PsycInfo Database Record (c) 2021 APA, all rights reserved)